Skip to main content

Table 2 IC50 of BTZ-resistant cells to DSF/Cu2+, CFZ and MG-132

From: Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

 

BTZ

CFZ

MG-132

DSF/Cu2+

 

IC50 (nM)

Fold

IC50 (nM)

Fold

IC50 (nM)

Fold

IC50 (nM)

Fold

CMY

2.9 ± 1.2

 

1.6 ± 0.4

 

210 ± 92

 

68 ± 14

 

CMY BR100

175 ± 59

60.4

44.7 ± 2.6

25.2

2345 ± 192

11.2

82 ± 15

1.2

CMY BR200

206 ± 40

71.0

55.5 ± 8.4

31.4

2540 ± 380

12.1

97 ± 27

1.4

CMK

4.3 ± 0.6

 

4 ± 1.6

 

303 ± 63

 

115 ± 30

 

CMK BR100

142 ± 46

33.0

73.7 ± 8

16.7

3512 ± 689

11.6

109 ± 15

0.95

  1. IC50 values are presented as mean ± standard deviation and expressed as fold difference compared to parent cell line. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, CFZ carfilzomib, DSF disulfiram
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us